Pharmacyte Biotech Stock Today
| PMCB Stock | USD 1.68 0.18 12.00% |
PerformanceWeak
| Odds Of DistressAbove Average
|
PharmaCyte Biotech is trading at 1.68 as of the 20th of March 2025, a 12.00 percent increase since the beginning of the trading day. The stock's open price was 1.5. PharmaCyte Biotech has over 57 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 18th of February 2025 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of September 2010 | Category Healthcare | Classification Health Care |
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. The company has 6.87 M outstanding shares of which 29.16 K shares are at this time shorted by private and institutional investors with about 0.56 trading days to cover. More on PharmaCyte Biotech
Moving against PharmaCyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
PharmaCyte Stock Highlights
| President CEO | Joshua Silverman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPharmaCyte Biotech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PharmaCyte Biotech's financial leverage. It provides some insight into what part of PharmaCyte Biotech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PharmaCyte Biotech (PMCB) is traded on NASDAQ Exchange in USA. It is located in 3960 Howard Hughes Parkway, Las Vegas, NV, United States, 89169 and employs 2 people. PharmaCyte Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.85 M. PharmaCyte Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.87 M outstanding shares of which 29.16 K shares are at this time shorted by private and institutional investors with about 0.56 trading days to cover.
PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check PharmaCyte Biotech Probability Of Bankruptcy
Ownership AllocationThe market capitalization of PharmaCyte Biotech is $10.85 Million. PharmaCyte Biotech holds 10.69 pct. of its outstanding shares held by insiders and 11.43 pct. owned by third-party entities. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the company is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check PharmaCyte Ownership Details
PharmaCyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Covestor Ltd | 2024-12-31 | 275 | |
| Planning Capital Management Corp | 2024-09-30 | 100.0 | |
| Royal Bank Of Canada | 2024-12-31 | 98.0 | |
| Bank Of America Corp | 2024-12-31 | 78.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 18.0 | |
| Sachetta Llc | 2024-12-31 | 14.0 | |
| Bfsg, Llc | 2024-12-31 | 5.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.0 | |
| Goss Wealth Management Llc | 2024-12-31 | 2.0 | |
| Vanguard Group Inc | 2024-12-31 | 192.4 K | |
| Geode Capital Management, Llc | 2024-12-31 | 164.7 K |
PharmaCyte Biotech Historical Income Statement
PharmaCyte Stock Against Markets
PharmaCyte Biotech Corporate Management
| CPA CPA | Chief Officer | Profile | |
| HansPeter Hammes | Member Consultant | Profile | |
| Jose MD | Consulting Officer | Profile | |
| HansPeter MD | Member Consultant | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.